ADDITIONAL VALUE OF TAU PROTEIN MEASUREMENT IN THE DIAGNOSIS OF CREUTZFELDT-JAKOB DISEASE

A tau fehérje meghatározás kiegészítő szerepe a Creutzfeldt-Jakob betegség diagnosztikájában

Edina Katalin Cseh[1], Gábor Veres[1,2], Krisztina Danics[3,4], Levente Szalárdy[1], Nikolett Nánási[1], Péter Klivényi[1], László Vécsei[1,2], Dénes Zádori[1]

Cseh EK, MSc; Veres G, PharmD, PhD; Danics K, MD; Szalárdy L, MD, PhD; Nánási N, MSc; Klivényi P, MD, PhD, DSc; Vécsei L, MD, PhD, DSc; Zádori D, MD, PhD

[1]Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary

[2]MTA-SZTE Neuroscience Research Group, Szeged, Hungary

[3]Prion Disease and Neuropathology Reference Center, Semmelweis University, Budapest, Hungary

[4]Department of Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary

Keywords: Creutzfeldt-Jakob disease, cerebrospinal fluid, biomarkers, 14-3-3 protein, **tau proteins, β-amyloid**

Kulcsszavak: Creutzfeldt-Jakob betegség, liquor, biomarkerek, 14-3-3 fehérje**, tau-fehérjék, β-amiloid**

Corresponding author (**levelező szerző**): Dénes Zádori MD, PhD
Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center,

University of Szeged, Semmelweis street 6, H-6725 Szeged, Hungary

Phone: +36 62 545351 Fax: +36 62 545597 E-mail: zadori.denes@med.u-szeged.hu

Abstract

Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) **and some other biomarkers** from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD.

Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged.

This preliminary study provided 100% sensitivity **for 14-3-3,** and interestingly, only 40% specificity **to support the clinical diagnosis of CJD**. Regarding tTau, the sensitivity values were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-off levels.

The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.

Absztrakt

Mivel jelenleg csak a pathológiai vizsgálat nyújt biztos diagnózist a Creutzfeldt-Jakob betegség (CJB) vonatkozásában, ezért különösen nagy szükség van olyan tesztekre, melyek még élő állapotban szolgáltatnak megfelelő diagnózist lehetőleg a betegség kezdeti stádiumában. Jelen tanulmány célja egy előzetes retrospektív analízis végzése volt a gyorsan progrediáló demenciával diagnosztizált betegek liquor totál tau (tTau) **és néhány egyéb biomarker** szintjének CJB diagnosztikájában való használhatóságáról.

A releváns klinikai adatok, valamint elektroenkefalográfiás és agyi mágneses magrezonanciás vizsgálati eredmények feldolgozása mellett a 14-3-3 fehérje kimutatása, továbbá a tTau szint meghatározása Western blot, illetve enzimhez kapcsolt immunoszorbens vizsgálatokkal történt 19, a Szegedi Tudományegyetem Neurológiai Klinikáján 2004-2017 között gyorsan progrediáló demenciával diagnosztizált beteg liquorából.

A jelen előzetes tanulmány **a CJB klinikai diagnózisának megerősítése vonatkozásában** 100%-os szenzitivitást, **ugyanakkor** meglepő módon, csak 40%-os specificitást mutatott a 14-3-3 fehérjére. A tTau esetén a szenzitivitás 100%-nak, illetve 83%-nak, míg a specificitás 71%-nak, illetve 86%-nak adódott a használt referenciaértéktől függően.

A 14-3-3 jelen tanulmányban kapott alacsony specificitása nem reprezentálja a szakirodalomban közölt adatokat, melynek hátterében a nem prion betegségek között a jelentős szövetkárosodással társuló kórképek nagyarányú előfordulása állhat, míg a tTau egyaránt jó szenzitivitást és specificitást mutatott. Valószínűleg a fenti anyagok és néhány új kémiai biomarker együttes alkalmazása a megfelelő szintre emelheti mind a szenzitivitást, mind a specificitást a CJB diagnosztikájában.

1. Introduction

Human transmissible spongiform encephalopathies, which include Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease (GSS), fatal familial insomnia (FFI), and kuru are rare neurodegenerative disorders, out of which CJD is by far the most common (1-2/1.000.000 person/year)[1]. Beside classic prion diseases, the prion-like propagation of the pathological process was raised in other neurodegenerative conditions, such as Alzheimer's disease (AD) and Parkinson's disease as well[2]. CJD is characterized by a rapid disease course associated with the conformational transformation of the human cellular prion protein (PrP^{c}) into the neurotoxic, protease-resistant scrapie form of this protein (PrP^{Sc})[3]. Considering the etiology of CJD, sporadic, familial, and acquired (variant and iatrogenic) forms are specified[3,4]. The sporadic form (sCJD) is the most common type, representing approximately 85% of all CJD cases with an unknown mechanism of infection[5]. It has 6 phenotypes, obtained from the combination of the methionine/valine (M/V) polymorphism in the coding region of the prion protein gene (*PRNP*) with the two isoforms of the PrP^{Sc}[6]. The genetic form of CJD (gCJD) accounts for 10-15% of the cases internationally[7]. The variant form of CJD (vCJD) shows a regional accumulation, mainly restricted to the United Kingdom and France, and it is known to be caused by consuming bovine spongiform encephalopathy-infected food[8]. The principal sources of iatrogenic CJD (iCJD) include contaminated growth hormone extracts and dura mater grafts derived from human cadavers with undiagnosed CJD infections, and it has an incidence of 1% of all CJD cases[9].

In addition to the presence of characteristic rapidly progressive dementia, the clinical picture may include the following clinical features: myoclonus, visual or cerebellar disturbance, pyramidal/extrapyramidal dysfunction, and akinetic mutism[10,11]**.** Along **with the demonstration of PrP in certain tissues with real-time quaking-induced conversion (RT-QuIC) AND/OR** typical electroencephalographic (EEG) findings during an illness of any

duration AND/OR a positive 14-3-3 cerebrospinal fluid (CSF) assay with a clinical duration to death < 2 years AND/OR high signal abnormalities in the caudate nucleus and putamen or at least two cortical regions (temporal-parietal-occipital) either in DWI or FLAIR sequences IF routine investigations do not suggest an alternative diagnosis, the diagnosis of probable or possible CJD can be set up depending on the number of matching factors[10–12]**.** The diagnosis of definite CJD requires comprehensive post-mortem neuropathological assessment[10,11]. Although the current diagnostic criteria list only 14-3-3 **and PrP**[4] as biomarker**s**, total tau (tTau), phosphorylated tau (pTau), α-synuclein, S100B protein[13–16]**,** neuron-specific enolase (NSE)[17], neurofilament light chain (NF-L)[18], phosphorylated neurofilament heavy chain (pNF-H)[18], and β-amyloid peptide (Aβ)[19] were also assessed for their suitability as biomarkers (Fig. 1.).

The presence of 14-3-3 protein in the CSF, which is characteristic of almost 95% of sCJD cases[17], **is currently measured by enzyme-linked immunosorbent assay (ELISA) instead of the previously widely applied Western blot method[20].** From the 7 known isomers (β, γ, ε, ζ, η, σ, and τ) only the presence of the β, γ, ε, and η forms has been demonstrated in CJD[21]. The tTau protein proved to be a useful biomarker in the diagnostic work up of different neurological diseases, including AD[22] and CJD, and together with the presence of 14-3-3 protein, they can reliably support the clinical diagnosis[13]. The tTau protein is highly increased in CJD, whereas this characteristic elevation cannot be observed for pTau[16,17]. In addition to the above-mentioned proteins, the levels of NF-L and pNF-H were found increased as well in both serum and CSF samples[18,23]. With regard to β-amyloid concentrations, similarly to AD, decreased values were reported compared to control groups[19,24,25]. It was demonstrated that S100B protein may have a role in the diagnosis of genetic prion diseases, including gCJD, GSS, and FFI, showing elevated concentrations beside the presence of the positivity of 14-3-3 and the increased level of NSE[17]. The level of α-synuclein protein, measured by electrochemiluminescence-based human **ELISA** kit, was considerably elevated in sCJD cases

compared to controls[15,26]. Furthermore, the confirmation of the presence of PrP^{Sc} in live patients was proposed to be included in the criteria for an *in vivo* definite diagnosis in the future[27]. **There are different techniques for the detection of PrP or PrP^{Sc} from different body fluids such as CSF, nasal brushing or blood samples[20], including the protein misfolding cyclic amplification (PMCA) assay, Western blotting, ELISA, RT-QuIC, the amyloid seeding assay (ASA), and the PrP aggregate formation assay (PAFA) for the measurement of the seeding activity of PrP^{Sc}[28].**

The measurement of β-amyloid peptide 1-42 ($A\beta_{1-42}$), tTau, and pTau proteins by ELISA method is available since 2009 in our institute for scientific purposes. Although the assessment of these 3 biomarkers may mainly have a supporting role in the clinical diagnosis of AD, but the above data may raise the possibility of the usefulness of particularly tTau protein in the diagnostic work up of CJD as well.

The aim of the present preliminary retrospective study was to measure the levels of tTau, pTau, and $A\beta_{1-42}$ in the CSF samples of our patients with the presumptive clinical diagnosis of CJD from 2004 to 2017, and to assess their potential supporting diagnostic role in the context of other available test results (such as EEG, brain **magnetic resonance imaging** (MRI), 14-3-3 protein measurement, genetic analysis, and neuropathological assessment). The findings of descriptive statistical analysis were compared with data from the biomarker literature.

2. Patients, materials, and methods

2.1 Sample collection and the work-up of clinical data

All patients with relatively rapidly progressive dementia with suspected CJD who underwent a lumbar puncture since 2004 at the Department of Neurology, University of Szeged were enrolled to this retrospective study, following the approval of the local Ethical Committee of

the University of Szeged (46/2014), adhering to the tenets of the most recent revision of the Declaration of Helsinki. For the clinical diagnosis of CJD according to the **criteria**[10,11]**,** in addition to the progressive dementia, the presence of the following 4 clinical features were assessed: myoclonus, visual or cerebellar disturbance, pyramidal/extrapyramidal dysfunction, and akinetic mutism. Furthermore, to be able to distinguish between possible and probable CJD, the available EEG and MRI findings were analyzed as well looking for periodic sharp wave complexes and high signal abnormalities in caudate nucleus and putamen or at least two cortical regions (temporal-parietal-occipital) either in DWI or FLAIR[29], respectively, along with the qualitative determination of CSF 14-3-3 protein with Western blot technique. The diagnosis of definite CJD was based on post-mortem neuropathological findings. The test results were supplemented with the data of genetic analysis (either *PRNP* gene mutation or codon 129 polymorphism) where available as well**, which examinations together with the determination of 14-3-3 protein were carried out at the Prion Disease and Neuropathology Reference Center, Semmelweis University, Budapest, Hungary, and Institute of Neurology, Medical University of Vienna, Vienna, Austria.** Patients with relatively rapidly progressive dementia who did not meet the diagnostic criteria for CJD were designated as non-prion rapidly progressive dementia (npRPD).

2.2 Determination of CSF total tau, phosphorylated tau, and beta-amyloid levels

Following the lumbar puncture, the CSF samples were centrifuged at 8.000 RPM for 10 min. The supernatants were stored in sterile polypropylene tubes in −80°C until use, distributed into aliquots to avoid repeated freeze–thaw cycles. We utilized commercially available ELISA kits (Innogenetics N.V., now Fujirebio Europe N.V., Ghent, Belgium) for the quantitative determination of $A\beta_{1-42}$, tTau, and pTau **(phosphorylated at threonine 181)** levels according

to the manufacturers' instruction, as described previously[30]. Briefly, all samples and standards were run in duplicates, the optical density values were detected at 450/560 nm with a plate reader (Awareness Technology Inc., Palm City, FL, USA) and the respective concentrations were read from the standard curves fitted by Sigmaplot 10.0 software (Systat Software Inc., Richmond, CA, USA). The lower limit of detection of the assays was 87, 87 and 15 pg/ml for $A\beta_{1-42}$, tTau, and pTau, respectively. The normal values provided by the reference manual are presented in the footnotes of Table 1. Where the measured values of tTau exceeded that of the highest standard, the actual highest standard values were given. Values were accepted if the respective coefficients of variation were less than 15%.

Our laboratory is approved for the diagnostic analyses of tTau, pTau, and $A\beta_{1-42}$, by the applied kits, for which we could use samples running in the 'Alzheimer's Association QC program for CSF biomarkers' as quality control samples to rule out analytical bias.

2.3 Statistical analyses

The sensitivity (i.e., the number of CJD patients with alteration in the observed parameter / (the number of CJD patients with alteration in the observed parameter + the number of CJD patients without alteration in the observed parameter)) and specificity (the number of npRPD patients without alteration in the observed parameter / (the number of npRPD patients without alteration in the observed parameter + the number of npRPD patients with alteration in the observed parameter)) values were calculated for all the laboratory biomarkers, and for the presence of characteristic findings on the EEG and MRI as well. Alteration in a chemical biomarker was considered if the CSF level was higher than the established cut-off for tTau and pTau and lower than that for $A\beta_{1-42}$, whereas CSF 14-3-3 was considered altered when it was positive. The cut-off values used and the method of their calculation are presented in the footnotes of Table 2. A

descriptive statistical analysis was carried out for the sensitivity and specificity values found in the scientific literature for all the above-mentioned and some other biomarkers.

3. Results

The clinical data (in light of the diagnostic criteria of CJD), the test results, and the autopsy findings (where applicable) of patients presenting with relatively rapidly progressive dementia **who underwent lumbar puncture** in the period of 2004-2017 at the University of Szeged, Department of Neurology are demonstrated in Table 1. The proportion of genetically determined CJD among CJD cases that underwent genetic analysis was remarkably high (6/7), which is in line with previous data reporting the gCJD form to predominate in this geographical area[31,32], contrasting with international data[7]. This is most probably not merely attributable to selection bias secondary to an influence by a positive family history, as this incidence is substantially high even if related to all consecutive CJD cases identified (6/12). Although, due to the limited number of cases in this preliminary study, a receiver operating characteristic (ROC) curve analysis cannot be carried out, the respective crude sensitivity and specificity values could be easily calculated by using the equations above, and these data are presented in Table 2. The specificity for CJD was found to be as surprisingly high as 100% in the cases of both the PSWCs in EEG and the characteristic alterations in MRI, but the sensitivity was only fair (75% and 80%, respectively). Among CSF biomarkers, only 14-3-3 and tTau provided 100% sensitivity (if mean + 1 SD of the reference values was applied as cut-off for tTau). However, the specificity of 14-3-3-positivity was considerably poor (40%), whereas that of tTau elevation was found to be fair (71%). If cut-off values were changed to > 1200 pg/ml for tTau (consistent with many of the studies in the literature), both good sensitivity (83%) and specificity (86%) values could be achieved. Due to the very limited number of cases where both measurement data were available, only an approximation could be carried out on the utility of

their combined use, providing a sensitivity of 87.5% and a specificity of 80%. The sensitivity values for pTau (25% in the case of both cut-off values) and $A\beta_{1-42}$ (50% and 17%, respectively) remained considerably low irrespective of the application of the upper quartile and the mean - 1 SD of the reference values as cut-offs, respectively, or > 60 pg/ml and < 400 pg/ml values (consistent with many of the studies in the literature), respectively. Surprisingly, the specificity values for pTau were found to be good (86% in both cases), irrespective of the applied cut-off values. However, the specificity values for $A\beta_{1-42}$ remained considerably low, irrespective of the applied cut-off values as well (29% and 57%, respectively).

4. Discussion

CJD is a rapidly progressive, fatal neurological disorder, where only autopsy provides definite diagnosis. Accordingly, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. In addition to the prognostic importance of the early diagnosis for the patients and their relatives, the possibility of disease transmission may raise hygienic considerations as well[33], despite the fact that CJD cannot be transmitted through direct contact or airborne spread[34]. Accordingly, only the standard precautions are to be complied with by the caregivers. However, in case of iatrogenic and variant forms, the direct implantation or transplantation of materials of human-origin or the consumption of infected bovine meat may result in disease transmission[35].

As mentioned above, at present, the definite diagnosis of CJD can only be established by confirming pathological prion protein deposition in the brain[36]. However, the probabilistic clinical diagnosis can be supported by the presence of PSWCs in EEG and/or abnormal signal changes on DWI or FLAIR MRI evaluated by a qualified neuroradiologist, trained to detect the characteristic signs for CJD. Both methods provide good specificity (74–100%[1,12,37,38] **and 83–**

100%[29,37,39], respectively), confirmed by the results of the current study as well (Table 2), but the sensitivity values are often only fair (32–66%[1,12,37,38] and 62.9–100%[37,39], respectively). Accordingly, the additional utility of several chemical biomarkers of neuronal damage were assessed to achieve a more precise diagnosis. The most commonly used chemical biomarker in CJD is the 14-3-3 protein[13,14,16], with sensitivity and specificity values ranging between 50% and 100% and between 40% and 97%, respectively[13,14,16,40]. Keeping in mind the heterogeneous nature of literature data, mainly as regards the composition of control groups, when studies using npRPDs as controls were selected to decrease the heterogeneity, the values remained almost the same. **Surprisingly, the results of the current study demonstrated an opposite pattern of sensitivity and specificity values, i.e., excellent sensitivity and poor specificity. On the one hand, the sensitivity values may be influenced by the presence of *PRNP* gene mutation or codon 129 polymorphism[16], which may have a special relevance to the current study as well due to the predominance of gCJD cases (E200K mutation) and MM genotype at codon 129. Although the presence of E200K mutation may slightly decrease the sensitivity, the MM genotype probably counteracts it. However, in light of the low number of cases, this hypothesis is at most speculative. The poor specificity of 14-3-3 may be the result of the small number of patients in the cohort with npRPD, including disorders with considerable tissue damage, such as carcinomatous meningitis or ischemic stroke, both of which can be accompanied with elevated CSF 14-3-3 levels[41,42]. However, CSF cytology or the assessment of MRI findings by a qualified neuroradiologist, respectively, may help in the exclusion of these entities behind the clinical picture of rapidly progressive dementia.** The second most commonly applied biomarker is the tTau protein[14,16,23], which is also considered to have a possible diagnostic value in light of its relatively high sensitivity (ranging between **75% and 94%**) and specificity (ranging between **84% and 97%**)[14]. With regard to the current study, if we applied the mean + 1 SD of the control values provided by the

manufacturer as cut-off level, a considerably high (100%) sensitivity value was achieved but the specificity remained only fair (71%). Although the limited number of samples did not allow the use of ROC analysis, the increase of the cut-off value to 1200 pg/ml, the cut-off reported in the majority of literature, resulted in the increase of specificity (86%) with a consequent decrease of sensitivity (83%), but in that case, both of them could be considered to be good. The utility of the combined use of these 2 biomarkers was assessed as well in some studies, resulting in a slightly decreased sensitivity **(49–92%[43,44])** but a considerable increase in specificity **(82–98%[43,44]**). Due to the reduced number of data for this analysis, the current study could not replicate this change. The statistical comparison of sensitivity and specificity values obtained in these complex studies demonstrated a significantly (**$p < 0.001$**) better specificity for tTau than **14-3-3[40]**.

Less data are available about the utility of other chemical biomarkers in the diagnostic work-up of CJD. The assessment of S100B[14], NSE[14], and PrP protein[19,45] for that purpose provided sensitivity values ranging between 65% and **82%, 73%** and 90% and **77% and 82.4%** respectively, with specificity values ranging between **76%** and 93%, 79% and **95%** and **82.1%** and 100% respectively. In light of these ranges, the diagnostic utility of these chemical biomarkers seemingly does not exceed those of 14-3-3 and tTau proteins; however, the considerably high specificity values draw attention to more and more widespread application of the determination of PrP protein.

The availability of literature data is limited with regard to the application of $A\beta_{1-42}$ peptide and pTau protein as chemical biomarkers in CJD, and it was proposed that these substances alone are not suitable as diagnostic markers for CJD, as their concentration values overlap with other neurological diseases[24,46]**. However, they may be relevant for the assessment of other neurodegenerative conditions OR concomitant pathologies in CJD, such as AD.** In line with these findings, the present study demonstrated poor sensitivity (50% or 17% if mean - 1

SD of the reference values provided by the manufacturer or 400 pg/ml levels were applied as cut-offs, respectively) and specificity values (29% or 57% if mean - 1 SD of the reference values provided by the manufacturer or 400 pg/ml levels were applied as cut-offs, respectively) for $A\beta_{1-42}$ peptide.

Although the current study showed good specificity values for pTau (86%, either the cut-off value was calculated as the upper quartile of the reference values according to the manual or a cut-off value of > 60 pg/ml was applied) similarly to those reported in the literature (**ranging between 58% and 95%[14])**, the sensitivity values remained considerably poor (25%, either the cut-off value was calculated as the upper quartile of the reference values according to the manual or a cut-off value of > 60 pg/ml was applied), in line with literature data ranging between 19.35% and **93%**[14,47]. **Accordingly, despite this good specificity values for pTau (phosphorylated at threonine 181), a recent neuropathological study suggest that it does not reliably reflect the tau pathology in CJD brains[48]. This is because pTau epitopes may vary considerably even within the same disease and that antibodies against this particular pTau epitope that is in fact assessed in most of the applied assays label the smallest amount of pathological tau alterations in post-mortem brains[4,48].**

Beside the above chemical biomarkers, some promising novel ones have been recently reported as well, including NF-L and pNF-H**, with considerably high sensitivity and specificity values[18,23].** Some recent studies[15,26] have reported larger than 95% sensitivity and specificity values for α-synuclein when comparing sCJD with the control group.

It can be concluded that despite the low number of cases, the present preliminary study replicated well the results of previous studies with large subject numbers**, except for the poor specificity value for 14-3-3**. In light of literature **data**, probably the measurement of 14-3-3 and tTau protein levels are the most widely used approaches to detect the characteristic pronounced neuronal damage in CJD. Recently, several attempts have been made by the

application of novel chemical biomarkers to increase the sensitivity and specificity for the diagnosis of CJD; however, except for the excellent specificity values for PrP, neither of them provided reliably high values near 100%. Accordingly, the combination of these tests may yield the best diagnostic value, keeping in mind the availability and preferably low cost of the methods as well.

5. Acknowledgements

This study was supported by the grants GINOP-2.3.2-15-2016-00034, EFOP-3.6.1-16-2016-00008, and National Brain Research Program 2017-1.2.1-NKP-2017-00002 NAP VI/4. Dénes Zádori was supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences. The authors would like to say special thanks to Gábor G Kovács, MD, PhD for providing the data of 14-3-3 measurement, genetic analysis and autopsy, where available, and for his valuable remarks during the composition of the manuscript.

6. References

1. *Collins SJ, Sanchez-Juan P, Masters CL, et al.* Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain J Neurol. 2006;129:2278–87. http://dx.doi.org/10.1093/brain/awl159
2. *Acquatella-Tran Van Ba I, Imberdis T, Perrier V.* From prion diseases to prion-like propagation mechanisms of neurodegenerative diseases. Int J Cell Biol. 2013;2013:975832. http://dx.doi.org/10.1155/2013/975832
3. *Prusiner SB.* Prions. Proc Natl Acad Sci U S A. 1998;95:13363–83.
4. *Kovacs GG.* Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci. 2016;17. https://dx.doi.org/10.3390/ijms17020189

5. *d'Aignaux JH, Cousens SN, Delasnerie-Lauprêtre N, et al.* Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998. Int J Epidemiol. 2002;31:490–5. http://dx.doi.org/10.1093/ije/31.2.490
6. *Kovács GG*. Genetic background of human prion diseases. Ideggyogy Sz. 2007;60:438–46.
7. *Kovács GG, Puopolo M, Ladogana A, et al.* Genetic prion disease: the EUROCJD experience. Hum Genet. 2005;118:166–74. https://dx.doi.org/10.1007/s00439-005-0020-1
8. *Will RG*. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull. 2003;66:255–65. https://dx.doi.org/1010.1093/bmb/66.1.255
9. *Johnson RT*. Prion diseases. Lancet Neurol. 2005;4:635–42. https://dx.doi.org/10.1016/S1474-4422(05)70192-7
10. *NCJDRSU*. The national CJD research and surveillance unit. 2018; http://www.cjd.ed.ac.uk/sites/default/files/criteria_0.pdf
11. *WHO*. WHO manual for surveillance of human transmissible spongiform encephalopathies, including variant Creutzfeldt-Jakob disease, Geneva: WHO. 2003.
12. *Zerr I, Pocchiari M, Collins S, et al.* Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2000;55:811–5. https://dx.doi.org/10.1212/WNL.55.6.811
13. *Ladogana A, Sanchez-Juan P, Mitrová E, et al.* Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol. 2009;256:1620–8. https://dx.doi.org/10.1007/s00415-009-5163-x
14. *Quadrio I, Perret-Liaudet A, Kovacs GG*. Molecular diagnosis of human prion disease. Expert Opin Med Diagn. 2011;5:291–306. https://dx.doi.org/10.1517/17530059.2011.576664

15. *Llorens F, Kruse N, Karch A, et al.* Validation of α-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease. Mol Neurobiol. 2018;55:2249–57. https://dx.doi.org/10.1007/s12035-017-0479-5

16. *Lattanzio F, Abu-Rumeileh S, Franceschini A, et al.* Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels. Acta Neuropathol. 2017;133:559–78. https://dx.doi.org/10.1007/s00401-017-1683-0

17. *Sanchez-Juan P, Green A, Ladogana A, et al.* CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006;67:637–43. https://dx.doi.org/10.1212/01.wnl.0000230159.67128.00

18. *Steinacker P, Blennow K, Halbgebauer S, et al.* Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737. https://dx.doi.org/10.1038/srep38737

19. *Dorey A, Tholance Y, Vighetto A, et al.* Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol. 2015;72:267–75. http://dx.doi.org/10.1001/jamaneurol.2014.4068

20. *Schmitz M, Ebert E, Stoeck K, et al.* Validation of 14-3-3 Protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic. Mol Neurobiol. 2016;53:2189–99. https://dx.doi.org/10.1007/s12035-015-9167-5

21. *Wiltfang J, Otto M, Baxter HC, et al.* Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem. 1999;73:2485–90. https://dx.doi.org/10.1046/j.1471-4159.1999.0732485.x

22. *Szalárdy L, Zádori D, Klivényi P, Vécsei L*. The role of cerebrospinal fluid biomarkers in the evolution of diagnostic criteria in Alzheimer's disease: shortcomings in prodromal diagnosis. J Alzheimers Dis. 2016;53:373–92. https://dx.doi.org/10.3233/JAD-160037

23. *Kovacs GG, Andreasson U, Liman V, et al.* Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017;24:1326–77. https://dx.doi.org/10.1111/ene.13389

24. *Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P*. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2003;74:1210–4. https://dx.doi.org/10.1136/jnnp.74.9.1210

25. *Goossens J, Bjerke M, Struyfs H, et al.* No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimers Res Ther. 2017;9:49. https://dx.doi.org/10.1186/s13195-017-0275-5

26. *Llorens F, Kruse N, Schmitz M, et al.* Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. J Alzheimers Assoc. 2017;13:710–9. https://dx.doi.org/10.1016/j.jalz.2016.09.013

27. *DeMarco ML*. Amplification of misfolded prion proteins in blood and cerebrospinal fluid for detection of Creutzfeldt-Jakob disease. Clin Chem. 2017;63:1671–3. http://dx.doi.org/10.1373/clinchem.2017.272229

28. *Kang H-E, Mo Y, Abd Rahim R, Lee H-M, Ryou C.* Prion diagnosis: application of real-time quaking-induced conversion. BioMed Res Int. 2017;2017:5413936. http://dx.doi.org/10.1155/2017/5413936

29. *Zerr I, Kallenberg K, Summers DM, et al.* Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132:2659–68. https://dx.doi.org/10.1093/brain/awp191

30. *Szalardy L, Zadori D, Simu M, Bencsik K, Vecsei L, Klivenyi P*. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-

osteopontin as a potential marker of clinical severity. J Neurol Sci. 2013;331:38–42. https://dx.doi.org/10.1016/j.jns.2013.04.024

31. *Mitrová E, Belay G*. Creutzfeldt-Jakob disease with E200K mutation in Slovakia: characterization and development. Acta Virol. 2002;46:31–9.
32. *Kovács GG, Bakos A, Mitrova E, Minárovits J, László L, Majtényi K*. Human prion diseases: the Hungarian experience. Ideggyogy Sz. 2007;60:447–52.
33. *Annus Á, Csáti A, Vécsei L*. Prion diseases: New considerations. Clin Neurol Neurosurg. 2016;150:125–32. http://dx.doi.org/10.1016/j.clineuro.2016.09.006
34. *Weinstein RA, Rutala WA, Weber DJ*. Creutzfeldt-Jakob Disease: recommendations for disinfection and sterilization. Clin Infect Dis. 2001;32:1348–56. https://dx.doi.org/10.1086/319997
35. *Szucs A, Várallyay P, Osztie E, et al.* Clinical experiences with Creutzfeldt-Jakob disease: three case studies. Ideggyogy Sz. 2012;65:401–10.
36. *Kovács GG, Kalev O, Budka H*. Contribution of neuropathology to the understanding of human prion disease. Folia Neuropathol. 2004;42:69–76. https://dx.doi.org/110.1002/9780470773512.ch4
37. *Tschampa HJ, Kallenberg K, Urbach H, et al.* MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain J Neurol. 2005;128:2026–33. https://dx.doi.org/10.1093/brain/awh575
38. *Heinemann U, Krasnianski A, Meissner B, et al.* Brain biopsy in patients with suspected Creutzfeldt-Jakob disease. J Neurosurg. 2008;109:735–41. https://dx.doi.org/10.3171/JNS/2008/109/10/0735
39. *Caobelli F, Cobelli M, Pizzocaro C, Pavia M, Magnaldi S, Guerra UP*. The role of neuroimaging in evaluating patients affected by Creutzfeldt-Jakob disease: a systematic

review of the literature. J Neuroimaging. 2015;25:2–13. http://dx.doi.org/10.1111/jon.12098

40. *Hamlin C, Puoti G, Berri S, et al.* A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2012;79:547–52. https://dx.doi.org/10.1212/WNL.0b013e318263565f

41. *Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF*. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology. 2001;56:1528–33. http://dx.doi.org/10.1212/WNL.58.3.509

42. *Koscova S, Zakova Slivarichova D, Tomeckova I, et al.* Cerebrospinal fluid biomarkers in the diagnosis of Creutzfeldt-Jakob disease in Slovak patients: over 10-year period review. Mol Neurobiol. 2017;54:5919–27. https://dx.doi.org/10.1007/s12035-016-0128-4

43. *Pennington C, Chohan G, Mackenzie J, et al.* The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt–Jakob disease. Neurosci Lett. 2009;455:56–9. https://dx.doi.org/10.1016/j.neulet.2009.02.067

44. *Forner SA, Takada LT, Bettcher BM, et al.* Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract. 2015;5:116–25. http://dx.doi.org/10.1212/CPJ.0000000000000111

45. *Orrú CD, Bongianni M, Tonoli G, et al.* A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371:519–29. https://dx.doi.org/10.1056/NEJMoa1315200

46. *Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E*. Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2001;71:401–3. https://dx.doi.org/10.1136/jnnp.71.3.401

47. *Hyeon JW, Kim SY, Lee J, et al.* Alternative application of tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory. Sci Rep. 2015;5:15283. https://dx.doi.org/10.1038/srep15283

48. *Kovacs GG, Rahimi J, Ströbel T, et al.* Tau pathology in Creutzfeldt-Jakob disease revisited. Brain Pathol Zurich Switz. 2017;27:332–44. https://dx.doi.org/10.1111/bpa.12411

7. Figure legend

Fig. 1. Some major physiological functions of certain chemical biomarkers, most frequently assessed in Creutzfeldt-Jakob disease